ReviewPublic health nursing (Boston, Mass.)
Determination of Seroprevalence of Chronic Hepatitis B, C and D: A Cross-Sectional Study From Türkiye.
Review in Public health nursing (Boston, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to determine the seroprevalence of hepatitis B, C, and D in Mardin, Türkiye, identify at-risk populations, and evaluate the effect of the hepatitis B vaccination program.
methodsHBsAg, anti-HBs, anti-HBc IgG, anti-HCV and anti-HDV results were analysed retrospectively.
resultsAmong the 30430 patients (60.2% female) tested, seropositivity rates were 2.1% for HBsAg, 55.2% for anti-HBs, 27.8% for anti-HBc IgG, and 0.14% for anti-HCV; of HBsAg-positive patients, 6.1% were anti-HDV positive. After adjusting for Mardin's age distribution, the age-weighted rates were 1.48%, 56.3%, 15.9%, 0.12%, and 6.2% (for anti-HDV in adults). Those born after 1998 (aged ≤ 26), when hepatitis B vaccination began nationally, had significantly lower HBsAg (0.3% vs. 2.8%) and anti-HBc IgG (2.5% vs. 36.6%) positivity, and higher anti-HBs (59.1% vs. 53.4%) positivity, than older individuals (p < 0.001). In a subgroup of 2703 with all hepatitis B markers, vaccine-induced immunity was more frequent in those aged ≤ 26 years (55.4% vs. 22.0%), while natural immunity (1.5% vs. 26.7%) and chronic infection (0.6% vs. 4.9%) were more common in those aged ≥ 27 years (p < 0.001).
conclusionThis large-scale survey in Mardin shows that hepatitis B vaccination reduced prevalence, highlighting the need for targeted screening and public health nursing interventions in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.